Market Overview:
Prostate cancer is a prevalent form of cancer affecting men's prostate gland. Castrate-resistant prostate cancer (CRPC) is an advanced form in which cancer still grows despite reducing testosterone levels. Treatment for CRPC includes chemotherapy, hormone therapy, immunotherapy, radiotherapy which reduces risk of painful symptoms.

Market key trends:
One of the key market trends is the approvals of new generation ... Read more

Castrate resistant prostate cancer (CRPC) is an advanced stage of prostate cancer that fails to respond to androgen deprivation therapy. It is more aggressive and difficult to treat compared to localized prostate cancer. The mainstay of treatment for CRPC includes chemotherapy drugs such as docetaxel, abiraterone acetate, enzalutamide, and cabazitaxel. However, these drugs provide only minimal increase in survival and are often associated with adverse effects compromising quality of life. ... Read more

Castrate resistant prostate cancer (CRPC) is an advanced stage of prostate cancer that fails to respond to androgen deprivation therapy. It is more aggressive and difficult to treat compared to localized prostate cancer. The mainstay of treatment for CRPC includes chemotherapy drugs such as docetaxel, abiraterone acetate, enzalutamide, and cabazitaxel. However, these drugs provide only minimal increase in survival and are often associated with adverse effects compromising quality of life. ... Read more